(S)-BI 665915

Request For Quotation
(S)-BI 665915 Suppliers list
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354;
Email: support@targetmol.com

(S)-BI 665915 manufacturers

  • (S)-BI 665915
  • (S)-BI 665915 pictures
  • $1970.00
  • 2026-04-20
  • CAS:1360550-05-5
  • Purity:
  • Supply Ability: 10g
  • (S)-BI 665915
  • (S)-BI 665915 pictures
  • $1970.00
  • 2025-07-26
  • CAS:1360550-05-5
  • Purity:
  • Supply Ability: 10g
(S)-BI 665915 Basic information
Product Name:(S)-BI 665915
Synonyms:(S)-BI 665915;(S) BI 665915,(S)BI 665915;1H-Pyrazole-1-acetamide, 4-[3-[(1S)-1-[4-(2-amino-5-pyrimidinyl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]-N,N-dimethyl-
CAS:1360550-05-5
MF:C24H26N8O2
MW:458.52
EINECS:
Product Categories:
Mol File:1360550-05-5.mol
(S)-BI 665915 Structure
(S)-BI 665915 Chemical Properties
Boiling point 738.8±70.0 °C(Predicted)
density 1.41±0.1 g/cm3(Predicted)
pka3.15±0.10(Predicted)
Safety Information
MSDS Information
(S)-BI 665915 Usage And Synthesis
Uses(S)-BI 665915 is an orally active oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitor with an IC50 of 1.7 nM for FLAP binding. (S)-BI 665915 inhibits FLAP functional in human whole blood with an IC50 of 45 nM. (S)-BI 665915 demonstrates an excellent cross-species agent metabolism and pharmacokinetics (DMPK) profile and a dose-dependent inhibition of LTB4 production[1].
in vivo

(S)-BI 665915 (oral; 1-100 mg/kg) demonstrates dose-dependent LTB4 production inhibition in mouse whole blood, 2 h after single oral dose[1].
(S)-BI 665915 (iv of 1 mg/kg or po of 10 mg/kg) shows low iv plasma clearance in all three species, with clearance values of 7 % Qh in rat, 2.8 % Qh in dog, and 3.6 % Qh in cynomolgus monkey, respectively. The volume of distribution (Vss) across species tested is in a range of 0.5 to 1.2 L/kg, and the bioavailability was good (45 to 63 %) in all species tested[1].

Animal Model:C57BL/6 mice[1]
Dosage:1, 3, 10, 30, 100 mg/kg (Pharmacokinetic Analysis)
Administration:Oral
Result:Demonstrated dose-dependent LTB4 production inhibition in mouse whole blood, 2 h after single oral dose.
Animal Model:Rat; dog; cynomolgus monkey[1]
Dosage:1 mg/kg (iv) or 10 mg/kg (po)
Administration:Iv or po
Result:Showed low iv plasma clearance in all three species, with clearance values of 7 % Qh in rat, 2.8 % Qh in dog, and 3.6 % Qh in cynomolgus monkey, respectively.
References[1] Takahashi H, et al. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915). J Med Chem. 2015 Feb 26;58(4):1669-90. DOI:10.1021/jm501185j
(S)-BI 665915 Preparation Products And Raw materials
Tag:(S)-BI 665915(1360550-05-5) Related Product Information
(S)-BI 665915 2-[4-[3-[(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl]-1,2,4-oxadiazol-5-yl]pyrazol-1-yl]-N,N-dimethylacetamide GSK2190915 10H-Pyridazino[1′,6′:4,5]pyrazino[2,1-c][1,4]oxazine-3,5-dione, 2-[(1S)-1-(1-chloro-2-naphthalenyl)ethoxy]-7,8,10a,11-tetrahydro-4-hydroxy-, (10aS)- Benzenebutanoic acid, 2,6-dichloro-α,γ-dioxo- 2(3H)-Furanone, 3-[(2,4-dihydroxyphenyl)methylene]-5-(4-methoxyphenyl)-